Angiogenesis: Regulators and clinical applications

Biochemical Pharmacology

Volumn 61, Issue 3, 2001, Pages 253-270

  Liekens, Sandra ^a   De Clercq, Erik ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Adhesion molecules; Angiogenesis; Endothelial cell proliferation and migration; Growth factors; Proteolytic enzymes; Tumor growth and metastasis

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ACETYLSALICYLIC ACID; AE 941; ALPHA INTERFERON; AMILORIDE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; COMBRETASTATIN A4; DISTAMYCIN A DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; GENISTEIN; LAVENDUSTIN A; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; MONOCLONAL ANTIBODY LM 609; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PRINOMASTAT; PROTAMINE; SURAMIN; TETRACYCLINE DERIVATIVE; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BASEMENT MEMBRANE; CANCER CHEMOTHERAPY; CELL ADHESION; CELL DIFFERENTIATION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; ENZYME RELEASE; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0035254648     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00529-3     Document Type: Article

References (225)

1. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Review: Angiogenesis: Implications for rheumatoid arthritis
4. Clinical applications of angiogenic growth factors and their inhibitors
5. Update on hemangiomas and vascular malformations
6. A flanking attack on cancer
7. Plasminogen activators and matrix metalloproteinases in angiogenesis
8. The roles of proteases in angiogenesis
9. uPA, uPAR, PAI-1, key intersection of proteolytic, adhesive and chemotactic highways?
10. Mechanisms for pro matrix metalloproteinase activation
11. Regulation of matrix metalloproteinase expression in tumor invasion
12. Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation andin vitro angiogenesis by fibroblast growth factor-2
13. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor
14. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-κB
15. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor
16. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1
17. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells
18. Tissue inhibitors of matrix metalloproteinases in cancer
19. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
20. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
21. Matrix metalloproteinases in tumour invasion and metastasis
22. Proteolysis in human breast and colorectal cancer
23. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications
24. Molecular angiogenesis
25. CXC chemokine modulation of angiogenesis: The importance of balance between angiogenic and angiostatic members of the family
26. Thymidine phosphorylase, 2-deoxy-d-ribose and angiogenesis
27. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis
28. TGF-β and the endothelium during immune injury
29. Transforming growth factor-β1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor
30. Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells
31. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis
32. VEGFs, receptors and angiogenesis
33. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
34. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesisin vitro
35. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
36. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
37. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
38. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
39. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1β
40. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
41. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
42. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells
43. Angiogenesis: How a tumor adapts to hypoxia
44. Vascular endothelial growth factor: Molecular and biological aspects
45. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia
46. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
47. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice
48. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
49. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
50. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing
51. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis
52. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
53. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
54. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
55. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells
56. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration
57. Human basic fibroblast growth factor gene encodes four polypeptides: Three initiate translation from non-AUG codons
58. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway
59. Role of soluble mediators in angiogenesis
60. Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway
61. Structural and functional diversity in the FGF receptor multigene family
62. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization
63. Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?
64. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2
65. Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas
66. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice
67. Proliferative hemangiomas: Analysis of cytokine gene expression and angiogenesis
68. Angiogenic factors as tumor markers
69. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
70. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
71. Cell adhesion and angiogenesis
72. The role of αv integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
73. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3
74. WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis
75. 3 promotes M21 melanoma growth in human skin by regulating tumor cell survival
76. v integrins
77. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
78. Cell adhesion molecules in angiogenesis
79. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1
80. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis
81. Characterization of E-selectin-deficient mice: Demonstration of overlapping function of the endothelial selectins
82. Impaired wound repair and delayed angiogenesis in aged mice
83. The rationale and future potential of angiogenesis inhibitors in neoplasia
84. Manipulating angiogenesis. From basic science to the bedside
85. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
86. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression
87. Establishing a link between oncogenes and tumor angiogenesis
88. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
89. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
90. The K-fgf/hst oncogene induces transformation through an autocrine mechanism that requires extracellular stimulation of the mitogenic pathway
91. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
92. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
93. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
94. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
95. Tumour suppression by the human von Hippel-Lindau gene product
96. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
97. Angiogenesis
98. Matrix metalloproteinases and metastasis
99. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
100. Modulation of angiogenesis in vitro
101. Assays for angiogenesis: A review
102. Quantitative angiogenesis assays: Progress and problems
103. Angiogenesis: Models and modulators
104. In vivo models of angiogenesis
105. Models for studying angiogenesis in vivo
106. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
107. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
108. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
109. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
110. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
111. Preclinical and clinical studies of MMP inhibitors in cancer
112. Tumor angiogenesis - New drugs on the block
113. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
114. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist
115. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
116. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin
117. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression
118. Angiogenesis: A dynamic balance of stimulators and inhibitors
119. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
120. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
121. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
122. Therapeutic potentials of angiostatin in the treatment of cancer
123. Angiostatin induces and sustains dormancy of human primary tumors in mice
124. Angiostatin binds ATP synthase on the surface of human endothelial cells
125. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis
126. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells
127. The generation of endostatin is mediated by elastase
128. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
129. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
130. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
131. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
132. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin
133. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells
134. 1 phase of the cell cycle
135. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor
136. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell linesin vitro andin vivo
137. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470
138. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption
139. A novel animal model for hemangiomas: Inhibition of hemangioma development by the angiogenesis inhibitor TNP-470
140. Thalidomide is an inhibitor of angiogenesis
141. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
142. Antitumor activity of thalidomide in refractory multiple myeloma
143. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
144. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
145. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
146. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
147. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
148. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
149. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth
150. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
151. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
152. Inhibition of fibroblast growth factors
153. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator
154. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals
155. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds
156. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound
157. Recent advances in the treatment of prostate cancer
158. Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma
159. Antiproliferative and angiostatic activity of suramin analogues
160. An update on the treatment of hemangiomas in children with interferon alfa-2a
161. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration
162. Successful treatment of infantile hemangiomas with interferon-α-2b
163. Clinical significance of angiogenic factors in breast cancer
164. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor
165. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
166. Prognostic significance of angiogenesis in human pancreatic cancer
167. Expression of platelet-derived endothelial cell growth factor and its mRNA in uterine endometrium during the menstrual cycle
168. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase
169. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
170. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
171. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
172. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
173. Combined effects of angiostatin and ionizing radiation in antitumour therapy
174. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
175. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
176. Tumor targeting with a selective gelatinase inhibitor
177. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
178. Viral vector-targeted anti-angiogenic gene therapy utilizing an angiostatin complementary DNA
179. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
180. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growthin vivo
181. A cancer therapy resistant to resistance
182. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis
183. Neoangiogenesis: A putative marker of malignancy in non-small-cell lung cancer (NSCLC) development
184. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer
185. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma
186. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
187. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
188. Activation mechanisms of matrix metalloproteinases
189. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
190. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors
191. Mechanism of action and in vivo role of platelet-derived growth factor
192. HGF/SF in angiogenesis
193. The codependence of angiogenesis and chronic inflammation
194. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
195. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro
196. Insulin, insulin-like growth factors, and vascular endothelium
197. The role of CXC chemokines in the regulation of angiogenesis
198. Human IL-3 stimulates endothelial cell motility and promotesin vivo new vessel formation
199. Prostaglandins and gangliosides of tumor microenvironment: Their role in angiogenesis
200. Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties
201. Oestrogen and endothelial cell angiogenic activity
202. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein
203. The role of hyaluronan in tumour neovascularization
204. Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation
205. Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: Biochemical characterization and biological consequences in endothelial cell cultures
206. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo
207. Recent developments in the cell biology of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: Activities on endothelial cells
208. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells
209. Angiopoietin-1 induces sprouting angiogenesisin vitro
210. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis
211. Troponin I is present in human cartilage and inhibits angiogenesis
212. Actions of TNF and IFN-γ on angiogenesis in vitro
213. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
214. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
215. Inhibition of angiogenesis by interleukin 4
216. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo
217. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids
218. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells
219. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression
220. Antiangiogenic tumour therapy: Will it work?
221. Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy
222. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors
223. Significance of angiogenesis in cancer therapy
224. Angiogenesis inhibitors
225. Aspirin for cancer